Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2206 to 2220 of 7682 results

  1. Datopotamab deruxtecan for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer [ID6435]

    Awaiting development [GID-TA11535] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Belzutifan for previously treated advanced renal cell carcinoma [ID6154]

    In development [GID-TA11086] Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments [ID6309]

    In development [GID-TA11546] Expected publication date: 10 September 2025

    Technology appraisal guidance
    In development

  4. myCOPD for managing chronic obstructive pulmonary disease (MTG68)

    Evidence-based recommendations on myCOPD for managing chronic obstructive pulmonary disease.

    Medical technologies guidance
    Published
    31 March 2022
    View recommendations

    Sections for MTG68

  5. Toripalimab with chemotherapy for treating advanced oesophageal squamous cell cancer without previous systemic chemotherapy [ID6414]

    Awaiting development [GID-TA11346] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. MT547 QuickChange Incontinence Wrap for urinary incontinence in men (MIB237)

      Status ...

    Medical technologies guidance
    Topic selection

  7. Suspected cancer update

    In development [GID-QS10176] Expected publication date: TBC

    Quality standard
    In development

  8. Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment [ID6370]

    In development [GID-TA11513] Expected publication date: 05 March 2025

    Technology appraisal guidance
    In development

  9. Acoramidis for treating transthyretin-mediated amyloidosis cardiomyopathy [ID6354]

    Awaiting development [GID-TA11415] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia when there is no 17p deletion or TP53 mutation and FCR (fludarabine, cyclophosphamide, rituximab) or BR (bendamustine, rituximab) are suitable [ID6291]

    In development [GID-TA11495] Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. An aortic cuff counterpulsation system for the treatment of heart failure

    Register an interest in this interventional procedure   ...

    Interventional procedures guidance
    Topic selection

  12. Extracorporeal bioartificial liver assist therapy

    Register an interest in this interventional procedure   ...

    Interventional procedures guidance
    Topic selection

  13. Chemical Component Separation

    Register an interest in this interventional procedure   ...

    Interventional procedures guidance
    Topic selection

  14. Transnasal endoscopy

    Register an interest in this interventional procedure   ...

    Interventional procedures guidance
    Topic selection

  15. Spinal Cord Stimulation Effective for HIV Neuropathy

    Register an interest in this interventional procedure   ...

    Interventional procedures guidance
    Topic selection